Gripgo tab. №100

Description

Gripgo №100 Composition
active substances: paracetamol (cacetine anhydrous), phenylephrine hydrochloride, phenylephrine hydrochloride, chlorpheniramine maleate;

1 tablet contains paracetamol 500 mg, caffeine anhydrous 30 mg, phenylephrine hydrochloride 10 mg, chlorpheniramine maleate 2 mg;

excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate.

Gripgo №100 Dosage form
Tablets.

Main physical and chemical properties: biconvex capsule-shaped white tablets.

Gripgo №100 Pharmacological group
Analgesics and antipyretics. Paracetamol, combinations without psycholeptics. ATX code N02B E51.

Pharmacological properties

Pharmacodynamics.

Gripgo® is a combination drug, the action of which is due to the components that are part of it.

Paracetamol is an antipyretic analgesic that has antipyretic and analgesic properties due to the effect of paracetamol on the hypothalamic thermoregulatory center and its ability to inhibit prostaglandin synthesis.

Caffeine is an alkaloid from the group of methylxanthines, which directly stimulates the respiratory and vascular centers of the brain, improves the physical and emotional state of patients, thereby reducing the manifestations of asthenia in infectious diseases. Increases the analgesic effect of paracetamol.

Pharmacokinetics.

Paracetamol is rapidly and almost completely absorbed in the gastrointestinal tract, the maximum concentration in blood plasma is reached in 30-60 minutes. The half-life from blood plasma is 1-4 hours. Evenly distributed throughout the body fluids. Protein binding is variable. The analgesic effect of the drug is 4-6 hours, antipyretic action – 6-8 hours. Excreted mainly by the kidneys in the form of conjugated metabolites, less than 5% is excreted unchanged.

Caffeine and its water-soluble salts are rapidly absorbed in the intestine (including the large intestine). The half-life from blood plasma is about 5-10 hours. The main part is demethylated and oxidized. About 10% is excreted by the kidneys unchanged.

Indications
Treatment of flu symptoms and other acute respiratory viral diseases: fever, headache, nasal congestion, rhinitis, sinusitis, sore throat, muscle aches, cough.

Contraindications
Hypersensitivity to any component of the drug, other derivatives of xanthines (theophylline, theobromine), opioids, antihistamines, sympathomimetic amines.
Severe cardiovascular disease, including unstable angina, decompensated heart failure, conduction disturbances, congenital prolonged QT interval or long-term use of drugs that prolong the QT interval, arrhythmias, bradycardia, severe atherosclerosis, including coronary vasospasm, predisposition to vascular disease , severe coronary heart disease; severe hypertension, acute myocardial infarction, organic diseases of the cardiovascular system.
Severe liver and kidney dysfunction.
Prostate adenoma with difficulty urinating, acute urinary retention in prostatic hypertrophy, obstruction of the bladder neck.
Gastric and duodenal ulcer in the acute stage, stenotic gastric and duodenal ulcer, pyloroduodenal obstruction; acute pancreatitis,
epilepsy.
Blood diseases (including severe anemia, leukopenia), violated hematopoiesis.
Endocrine diseases (hyperthyroidism, diabetes, pheochromocytoma, thyrotoxicosis).
Lung diseases, including bronchial asthma; risk of respiratory failure.
Angular glaucoma.
Glucose-6-phosphate dehydrogenase deficiency.
Alcoholism.
Increased excitability, sleep disorders, epilepsy, alcoholism.
Congenital hyperbilirubinemia.
Old age.
Concomitant use with tricyclic antidepressants, ß-blockers; with MAO inhibitors and within 2 weeks after discontinuation of their use.